Skip to main content
Premium Trial:

Request an Annual Quote

Additional Genes

A new genetic testing service for cancer patients is being introduced in Wales, BBC News reports.

It adds that cancer patients in Wales will be able to undergo testing through the Cymru Service for Genomic Oncology Diagnoses, which is part of the All Wales Medical Genomic Service, to detect changes in about 500 different genes, up from the 50 genes current examined. This, Rhian White, the head cancer genomics clinical scientist there says, means that more tumor types can undergo testing. The service also plans to expand testing capacity over the next decade, the BBC notes.

By expanding testing, the hope is to uncover targeted therapies from which patients might better benefit. "Where we compare the newer anti-cancer targeted therapies with more traditional therapies, like chemotherapy, we know the outcomes are often better in terms of controlling the cancer better and helping patients live for longer," Samantha Cox, a clinical oncologist, tells the BBC.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.